Scotiabank Initiates Coverage On Travere Therapeutics with Sector Outperform Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Travere Therapeutics with a Sector Outperform rating and set a price target of $23.
October 16, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has initiated coverage on Travere Therapeutics with a Sector Outperform rating and a price target of $23, indicating a positive outlook.
The initiation of coverage with a Sector Outperform rating and a specific price target of $23 by Scotiabank suggests a positive sentiment towards Travere Therapeutics. This could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100